Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

Br J Dermatol. 2020 Aug;183(2):404-406. doi: 10.1111/bjd.19161. Epub 2020 Jun 10.

Abstract

We wish to bring your attention to the PsoPROTECT (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid‐19 infecTion) and SECURE‐AD (Surveillance Epidemiology of Coronavirus Under Research Exclusion‐Atopic Dermatitis) registries; two urgent global initiatives that address an unmet need for delineating the determinants of COVID‐19 outcomes in the common cutaneous immune‐mediated inflammatory diseases (IMIDs) psoriasis and atopic dermatitis.

Publication types

  • Letter

MeSH terms

  • Betacoronavirus / immunology*
  • Betacoronavirus / isolation & purification
  • COVID-19
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy
  • Coronavirus Infections / virology
  • Datasets as Topic
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / immunology*
  • Global Burden of Disease / statistics & numerical data*
  • Humans
  • Immunologic Factors / therapeutic use
  • International Cooperation
  • Observational Studies as Topic
  • Pandemics
  • Patient Reported Outcome Measures
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy
  • Pneumonia, Viral / virology
  • Psoriasis / drug therapy
  • Psoriasis / immunology*
  • Registries / statistics & numerical data
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Immunologic Factors